Dr. Reddy’s announced the launch of Treprostinil Injection in the U.S. market, a therapeutic equivalent generic version of Remodulin Injection, approved by the FDA.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RDY:
- Aditxt in asset purchase pact to acquire 50% of of Global Response Aid
- Coya Therapeutics enters worldwide COYA 302 agreement with Dr. Reddy’s
- Dr. Reddy’s upgraded to Buy from Neutral at BofA
- Journey Medical announces completion of treatment assessing DFD-29’s impact
- Dr. Reddy’s to acquire Mayne Pharma for upfront payment of $90M